Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients

@article{Hu2010PharmacogeneticAO,
  title={Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients},
  author={M. Hu and S. Lui and Valiant W.L. Mak and T. Chu and V. Lee and E. Poon and T. Tsui and G. Ko and L. Baum and L. Tam and E. Li and B. Tomlinson},
  journal={Pharmacogenetics and Genomics},
  year={2010},
  volume={20},
  pages={634-637}
}
Lipid changes with statin treatments vary greatly between individuals for reasons which are largely unknown. This study was performed to examine the genetic determinants of lipid responses to rosuvastatin in Chinese patients. A total of 125 polymorphisms in 61 candidate genes from 386 Chinese patients were analyzed for association with the lipid responses to rosuvastatin 10 mg daily. The polymorphisms most highly associated with the low-density lipoprotein cholesterol (LDL-C) response were 421C… Expand
41 Citations
Pharmacogenomics of lipid-lowering therapies.
  • 17
Lipid-lowing pharmacogenomics in Chinese patients
  • 2
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 10 REFERENCES
ABCG2 Polymorphism Is Associated With the Low‐Density Lipoprotein Cholesterol Response to Rosuvastatin
  • 118
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
  • W. Zhang, B. Yu, +9 authors H. Zhou
  • Medicine
  • Clinica chimica acta; international journal of clinical chemistry
  • 2006
  • 227
A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin
  • C. White
  • Chemistry, Medicine
  • Journal of clinical pharmacology
  • 2002
  • 193
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
  • 416
Human flavin-containing monooxygenases.
  • 253
Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter.
  • 122